Middletown Life

Author: Zhongshan Kangfang Biological Medicine Co., LTD

Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026

April 7, 2026
Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026

March 31, 2026
Akeso Reports Full-Year 2025 Financial Results

March 27, 2026
Akeso Advances “IO 2.0 + ADC 2.0” Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab

March 24, 2026
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

March 15, 2026
Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results

March 4, 2026
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

March 4, 2026
Akeso’s IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications

February 13, 2026
Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer

February 12, 2026
Ivonescimab Included in FirstWord Pharma’s “The Drugs That Will Shape 2026”

January 29, 2026